Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ESRRA | P11474 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588204 | 0.87 | ESRRA (0.61) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL15026337 | 0.83 | ESRRA (0.54) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL13087004 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL14924117 | 0.81 | ESRRA (0.71) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL14924107 | 0.80 | ESRRA (0.65) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL14924043 | 0.78 | ESR2 (0.77) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL14924075 | 0.78 | ESR2 (0.58) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL14915834 | 0.77 | ESRRA (0.71) | KDM4EALDH1A1ESRRAESR2TP53 | |
| SCHEMBL14924129 | 0.76 | ESRRA (0.63) | ESRRAESR2TP53LMNATHRB | |
| SCHEMBL14924108 | 0.76 | ESRRA (0.63) | KDM4EALDH1A1ESRRAESR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | KDM4E 1789/4885ALDH1A1 1489/4885ESRRA 3/4885 |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | KDM4E 901/4885ALDH1A1 250/4885ESRRA 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.